GLP1R and type 2 diabetes mellitus: However, a meta‐analysis of more than 55 000 participants from cardiovascular outcome trials in people with type 2 diabetes using GLP‐1 receptor agonists (including semaglutide and liraglutide) at doses used to treat type 2 diabetes did not detect a signal for these events over 175 000 patient‐years of observation.46